67 related articles for article (PubMed ID: 9413208)
1. In vivo effects of cyclophosphamide on oncogene and suppressor gene expression in a "follow up" study.
Ember I; Kiss I
Anticancer Res; 1997; 17(5A):3593-7. PubMed ID: 9413208
[TBL] [Abstract][Full Text] [Related]
2. In vivo effects of CHOP protocol on onco and suppressor gene expression: follow-up study.
Ember I; Kiss I; Raposa T; Nowrasteh G; Matolcsy A
In Vivo; 1998; 12(5):489-94. PubMed ID: 9827356
[TBL] [Abstract][Full Text] [Related]
3. Effect of E-2-(4'-methoxybenzylidene)-1-benzosuberone on the 7,12-dimethylbenz[alpha]anthracene-induced onco/suppressor gene action in vivo. I: A 24-hour experiment.
Perjési P; Bayer Z; Ember I
Anticancer Res; 2000; 20(1A):475-81. PubMed ID: 10769699
[TBL] [Abstract][Full Text] [Related]
4. In vivo effects of COPP protocol on onco- and suppressor gene expression in a 'follow up study'.
Ember I; Kiss I; Raposa T
In Vivo; 1997; 11(5):399-402. PubMed ID: 9427043
[TBL] [Abstract][Full Text] [Related]
5. Effect of ABVD therapeutic protocol on oncogene and tumor suppressor gene expression in CBA/Ca mice.
Ember I; Kiss I; Ghodratollah N; Raposa T
Anticancer Res; 1998; 18(2A):1149-52. PubMed ID: 9615780
[TBL] [Abstract][Full Text] [Related]
6. Effect of rancid corn oil on some onco/suppressor gene expressions in vivo. A short-term study.
Perjési P; Pintér Z; Gyöngyi Z; Ember I
Anticancer Res; 2002; 22(1A):225-30. PubMed ID: 12017293
[TBL] [Abstract][Full Text] [Related]
7. Early effect of cyclophosphamide on oncogene expression in vivo.
Ember I; Kiss I; Vermes E
In Vivo; 1998; 12(2):201-7. PubMed ID: 9627803
[TBL] [Abstract][Full Text] [Related]
8. Early modification of c-myc, Ha-ras and p53 expressions by chemical carcinogens (DMBA, MNU).
Budán F; Varjas T; Nowrasteh G; Prantner I; Varga Z; Ember A; Cseh J; Gombos K; Pázsit E; Gobel G; Bauer M; Gracza T; Arany I; Perjési P; Ember I; Kiss I
In Vivo; 2009; 23(4):591-8. PubMed ID: 19567395
[TBL] [Abstract][Full Text] [Related]
9. Effect of cisplatin treatment on early activation of oncogenes in vivo.
Németh A; Gyöngyi Z; Nádasi E; Ember A; Olasz L; Nyárády Z; Skapinyecz J; Ember I
In Vivo; 2002; 16(5):307-10. PubMed ID: 12494868
[TBL] [Abstract][Full Text] [Related]
10. Effect of 7,12-dimethylbenz(a)anthracene on onco/suppressor gene action in vivo: a short-term experiment.
Ember I; Kiss I; Pusztai Z
Anticancer Res; 1998; 18(1A):445-7. PubMed ID: 9568117
[TBL] [Abstract][Full Text] [Related]
11. Effect of E-2-(4'-methoxybenzylidene)-1-benzosuberone on the 7,12-dimethylbenz[alpha]anthracene-induced onco/suppressor gene action in vivo II: A 48-hour experiment.
Perjési P; Gyöngyi Z; Bayer Z
Anticancer Res; 2000; 20(3A):1839-48. PubMed ID: 10928116
[TBL] [Abstract][Full Text] [Related]
12. Early modification of c-myc, Ha-ras and p53 expressions by N-methyl-N-nitrosourea.
Budán F; Varjas T; Nowrasteh G; Varga Z; Boncz I; Cseh J; Prantner I; Antal T; Pázsit E; Gobel G; Bauer M; Gracza T; Perjési P; Ember I; Gyöngyi Z
In Vivo; 2008; 22(6):793-7. PubMed ID: 19181008
[TBL] [Abstract][Full Text] [Related]
13. Changes in expression of onco- and suppressor genes in peripheral leukocytes--as potential biomarkers of chemical carcinogenesis.
Gyöngyi Z; Ember I; Kiss I; Varga C
Anticancer Res; 2001; 21(5):3377-80. PubMed ID: 11848497
[TBL] [Abstract][Full Text] [Related]
14. Early effects of cyclosporin A on in vivo oncogene expression.
Ember I; Kiss I; Dezsényi E; Kertai P
Anticancer Res; 1994; 14(3A):1095-6. PubMed ID: 8074456
[TBL] [Abstract][Full Text] [Related]
15. Different H2 haplotypes have a strong influence on oncogene action.
Ember I; Kiss I; Nowrasteh G
Anticancer Res; 1999; 19(2A):1181-5. PubMed ID: 10368672
[TBL] [Abstract][Full Text] [Related]
16. Early effects of transplatin on oncogene activation in vivo.
Németh A; Nádasi E; Beró A; Olasz L; Ember A; Kvarda A; Bujdosó L; Arany I; Csejtei A; Faluhelyi Z; Ember I
Anticancer Res; 2004; 24(6):3997-4001. PubMed ID: 15736445
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with SCH58500 (p53 adenovirus) and cyclophosphamide in preclinical cancer models.
Nielsen LL
Oncol Rep; 2000; 7(6):1191-6. PubMed ID: 11032912
[TBL] [Abstract][Full Text] [Related]
18. Early effects of different cytostatic protocols for head and neck cancer on oncogene activation in animal experiments.
Németh A; Nadasi E; Gyöngyi Z; Olasz L; Nyarady Z; Ember A; Kvarda A; Bujdoso L; Arany I; Kiss I; Csejtey I; Ember I
Anticancer Res; 2003; 23(6C):4831-5. PubMed ID: 14981932
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
20. In vivo effects of afobazole (2-mercaptobenzimidazole derivative) on the 7,12-dimethylbenz [alpha]anthracene-induced oncogene and suppressor gene expression.
Szanyi I; Lujber L; Gerlinger I; Pytel J; Bauer M; Csejtey A; Szele E; Gombos K; Kiss I; Seredenin S; Yarkova M; Ember I
In Vivo; 2007; 21(6):1059-63. PubMed ID: 18210756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
